首页 / 院系成果 / 成果详情页

Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update 期刊论文

编号：

08FFD22C5AE7608BBF6FC4C7BBD221F7
作者：

Wang, Chengshuo(王成硕)#^[1,2,3,4,5]Bao, Yixiao(鲍一笑)#^[6]Chen, Jianjun(陈建军)#^[7]Chen, Xiaoyang#^[8]Cheng, Lei(程雷)#^[9,10]Guo, Yin Shi(郭胤仕)#^[11]Hao, Chuangli(郝创利)#^[12]Lai, He#^[13]Li, Huabin(李华斌)#^[14]Li, Jing(李靖)#^[15]Liu, Changshan(刘长山)#^[16]Liu, Yun(刘昀)#^[17]Liu, Zheng(刘争)#^[18]Lou, Hongfei(娄鸿飞)#^[1,4]Lv, Wei(吕威)#^[19]Nong, Guangmin(农光民)#^[20]Qiu, Qianhui(邱前辉)#^[21]Ren, Xiumin(任秀敏)#^[22]Shao, Jie(邵洁)#^[23]Shen, YiHong(沈毅弘)#^[24]Shi, Li(史丽)#^[25]Song, XiCheng(宋西成)#^[26]Song, Yuxin#^[27]Tang, Suping#^[28]Wang, Hongtian(王洪田)#^[29]Wang, Xiangdong(王向东)#^[1,2,3]Wang, Xueyan(王学艳)#^[29]Wang, Zhenlin(王振霖)#^[30]Wei, Qingyu(魏庆宇)#^[31]Xie, Hua#^[32]Xing, Zhimin(邢志敏)#^[33]Xu, Rui(徐睿)#^[34]Xu, Yu(许昱)#^[35]Yang, Qintai(杨钦泰)#^[36]Yao, Hongmei#^[37]Ye, Jing(叶菁)#^[38]You, Yiwen(尤易文)#^[39]Yu, Hongmeng(余洪猛)#^[14]Yu, Yongmei(余咏梅)#^[40]Zhang, Huanping#^[41]Zhang, Gehua(张革化)#^[36]Zhang, Yuan(张媛)#^[5]Zhi, Yuxiang(支玉香)#^[42]Zhou, Weikang#^[43]Zhu, Li(朱丽)#^[44]Zhu, Xinhua(朱新华)#^[45]Chai, Ruonan(柴若楠)^[32]Chen, Dehua(陈德华)^[34]Guan, Kai(关凯)^[42]Huang, Zizhen(黄子真)^[36]Huang, Yanran^[1];Ma, Tingting(马婷婷)^[29]Ma, Yuemei(马月眉)^[46]Meng, Yifan(孟一帆)^[1]Ren, Lei^[5];Wang, Jianxing^[22];Wang, Nan(王男)^[18]Xian, Mo(鲜墨)^[15]Xiang, Rong(向荣)^[35]Zheng, Ming^[1];Zhang, Luo(张罗)*^[1,5]
语种：

英文
期刊：

ALLERGY ASTHMA & IMMUNOLOGY RESEARCH ISSN：2092-7355 2022 年 14 卷 6 期 (604 - 652) ; NOV
收录：
关键词：

Allergen immunotherapy allergic rhinitis guidelines China immunoglobulin E biomarkers rush immunotherapy house dust mites subcutaneous immunotherapy
摘要：

In the last few decades, there has been a progressive increase in the prevalence of allergic rhinitis (AR) in China, where it now affects approximately 250 million people. AR prevention and treatment include allergen avoidance, pharmacotherapy, allergen immunotherapy (AIT), and patient education, among which AIT is the only curative intervention. AIT targets the disease etiology and may potentially modify the immune system as well as induce allergen -specific immune tolerance in patients with AR. In 2017, a team of experts from the Chinese Society of Allergy (CSA) and the Chinese Allergic Rhinitis Collaborative Research Group (C2AR2G) produced the first English version of Chinese AIT guidelines for AR. Since then, there has been considerable progress in basic research of and clinical practice for AIT, especially regarding the role of follicular regulatory T (TFR) cells in the pathogenesis of AR and the use of allergen-specific immunoglobulin E (sIgE) in nasal secretions for the diagnosis of AR. Additionally, potential biomarkers, including TFR cells, sIgG4, and sIgE, have been used to monitor the incidence and progression of AR. Moreover, there has been a novel understanding of AIT during the coronavirus disease 2019 pandemic. Hence, there was an urgent need to update the AIT guideline for AR by a team of experts from CSA and C2AR2G. This document aims to serve as professional reference material on AIT for AR treatment in China, thus improving the development of AIT across the world.
推荐引用方式
GB/T 7714：

Wang Chengshuo,Bao Yixiao,Chen Jianjun, et al. Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update [J].ALLERGY ASTHMA & IMMUNOLOGY RESEARCH,2022,14(6):604-652.
APA：

Wang Chengshuo,Bao Yixiao,Chen Jianjun,Chen Xiaoyang,&Zhang Luo.(2022).Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update .ALLERGY ASTHMA & IMMUNOLOGY RESEARCH,14(6):604-652.
MLA：

Wang Chengshuo, et al. "Chinese Guideline on Allergen Immunotherapy for Allergic Rhinitis: The 2022 Update" .ALLERGY ASTHMA & IMMUNOLOGY RESEARCH 14,6(2022):604-652.
入库时间：

2022/12/3 21:53:30
更新时间：

2022/12/3 21:53:30

浏览次数：167  下载次数：0

分享到：

浏览次数：167

下载次数：0

打印次数：0